Talk:DLL3

Possible target for small-cell lung cancer (SCLC)

Expert Examines Immunotherapy Potential in Small Cell Lung Cancer says "DLL3 is a molecule that is expressed on about two-thirds of SCLCs, and it is actually a functionally active molecule. It’s a NOTCHED ligand that inhibits NOTCH1. That activates CO1, which is a main driver of SCLC. Therefore, Stemcentrx linked a drug to an antibody against DLL3 with a chemotherapy drug and showed that there was a high response rate in the second- and third-line setting of SCLC." rovalpituzumab tesirine - Rod57 (talk) 14:25, 19 May 2016 (UTC)[reply]

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.